Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. - Test2 - elhamkhani - TriplyDB

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

http://www.wikidata.org/entity/Q37114828

about

Tuberculosis vaccine types and timings Immunoregulatory functions and expression patterns of PE/PPE family members: Roles in pathogenicity and impact on anti-tuberculosis vaccine and drug design Prime-boost approaches to tuberculosis vaccine development AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis High Sequence Variability of the ppE18 Gene of Clinical Mycobacterium tuberculosis Complex Strains Potentially Impacts Effectivity of Vaccine Candidate M72/AS01E Conserved immune recognition hierarchy of mycobacterial PE/PPE proteins during infection in natural hosts Monkey models of tuberculosis: lessons learned Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis Simultaneous immunization against tuberculosis Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing Novel vaccination strategies against tuberculosis.Mycobacterial PE/PPE proteins at the host-pathogen interface.Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods.Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis.Polyclonal activation of naïve T cells by urease deficient-recombinant BCG that produced protein complex composed of heat shock protein 70, CysO and major membrane protein-II Definition of Mafa-A and -B haplotypes in pedigreed cynomolgus macaques (Macaca fascicularis)Extensive DRB region diversity in cynomolgus macaques: recombination as a driving force Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints.Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.Evolution of smooth tubercle Bacilli PE and PE_PGRS genes: evidence for a prominent role of recombination and imprint of positive selection Immunostimulatory activity of major membrane protein II from Mycobacterium tuberculosis Modeling tuberculosis in nonhuman primates.A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants.Development of new vaccines and drugs for TB: limitations and potential strategic errors Vaccine against tuberculosis: what's new?Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection The contribution of non-human primate models to the development of human vaccines Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.An aerosol challenge model of tuberculosis in Mauritian cynomolgus macaques.A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents.

P2860

Q26862762-60163A49-9D06-4905-BE93-B4565AD62DEA Q27013243-37DD4A47-0381-4952-877B-A59B721CB816 Q27024526-7787482A-E6F3-493B-90B7-9080B47F0930 Q27300923-2D2D9209-1255-476E-8661-BA74929C3AB6 Q27309052-E8FDB28B-424B-4A87-92B2-64B9223D60DF Q27315911-E377F35B-6DC1-428E-9DD8-34F484A33F60 Q27316557-E7F99D79-C20F-4292-A896-7B2E3F9392CC Q27333759-6286FE9D-831C-4AD3-85BB-E82E7289A52F Q28081586-B657B13F-1242-4B9D-B47F-609EE423F0C7 Q28730427-84A9EC3F-2C03-4AB3-AE04-811D32A75287 Q28742666-5BF9325D-6B8A-48B9-8125-C37348D4B5E9 Q30227121-BFB975D3-36AF-4FEF-8E54-27C4FC67F78C Q30363188-CDC9E050-49F7-4073-81E2-A4E2D870BD17 Q30399629-7BF5ACED-AA72-47EE-BBA4-6E690C28D1B8 Q31154267-6300BCD6-91AA-44A3-938C-37ABBFB2F62A Q33518452-6FCDF967-DBBF-4F3C-B13B-8293FD2D2178 Q33547708-35359732-A472-4A7B-B615-9130746D6103 Q33573078-747DD496-71A8-4B9E-8614-0FB852875561 Q33574971-F0E85948-D072-4836-9345-D3DB73789B61 Q33684976-B8905D31-4368-4948-95BC-7207E1948221 Q34146613-716BC4F0-3D19-405E-81D3-1B199743B3AE Q34229760-B4AAC8ED-ABEA-4598-ABF0-2E868B7DF7D5 Q34289930-2D5CF0FD-3630-4B76-B816-E1230F05681F Q34298351-E9E8E6B0-2DDC-4A69-BAF7-36AEDBEEDD56 Q34738154-D29C5A7F-6CD0-42D9-A38A-F20BF03C9EF0 Q34738803-42DBF9EC-3E2B-4007-AAD2-CFC555B5A669 Q34930509-CA1B0031-51B5-4E73-B601-9074308A5F81 Q35033838-B4B36B02-25BE-4910-A840-AB54C0BAC6FF Q35055158-1514579B-E7FB-4519-9B2F-06F8124BC157 Q35065531-217BBE00-08ED-43FE-BF90-706B4BE901B4 Q35101472-E60BA665-B8B9-4441-A243-AC7B5FDD9F9A Q35135987-0E73BCB4-35FF-4C34-9733-C2D36A41DF69 Q35139265-0F1CAE52-DEDF-4D3C-8BDA-0FAD7F10C3D1 Q35301384-35ED7A95-4272-40E6-97EA-73561A82F7EC Q35640563-2F6AB76A-84D0-4F83-8BAB-005C9622579D Q35737990-F17676F6-F318-423A-84C9-705FC4C683AA Q35772893-8B8FF1DB-128E-4CF6-874F-1536D8E0BE75 Q35809113-59E8D0E3-B260-4C9A-A432-454549544BF9 Q36300666-1D254332-DFF7-4700-834D-2AE36CE1BA22 Q36338571-512A6E8F-BC4C-495A-B65F-3F9BEF1EAAA0

P2860

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

http://www.wikidata.org/entity/Q37114828

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@en

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@nl

type

label

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@en

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@nl

prefLabel

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@en

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@nl

P1433

Q37114828-B483915D-7B80-49DB-884F-B6F98BDE9359

P1476

Q37114828-1F6AC092-C57A-4624-BF02-99EEF07EBB97

P2093

Q37114828-18927323-C51F-4DF9-A4BC-40A6F0D78CF4

Q37114828-2748296F-8172-4B30-B17E-337D7BC1316C

Q37114828-459F71EF-5578-4ED1-81CA-0F5843777973

Q37114828-487B77FC-90EC-450E-9160-33062D381442

Q37114828-6F5F994F-F25A-4D81-BBF3-41222EAFF143

Q37114828-832EC51E-C8BD-4D67-982A-1753D1DE28F2

Q37114828-896B3E93-EA4D-42BB-8026-9B8C3E1F736E

Q37114828-981A0EBD-64CF-4144-9366-4B2C009479BF

Q37114828-9EA56B2A-0478-4E15-B345-495E23EB8ED7

Q37114828-AECAD539-5CE1-4214-BB19-850DE374D6BD

P2860

Q37114828-28B67E6A-8E8F-4484-90F9-C1D2E120E78C

Q37114828-28D9AEB4-10A7-4A2E-9D4C-19CCA4CF3A1E

Q37114828-45E0F707-FF83-419C-A514-3C32BC30A642

Q37114828-51E2B303-DEB0-45EF-8206-6EC58724A27C

Q37114828-61657CA3-37ED-4F13-88EE-430D7FF55C12

Q37114828-61A234CE-A4E0-49E9-8BDE-D32EC91B7975

Q37114828-63D61753-6714-4FF1-8A84-28D010058C9B

Q37114828-6592DB98-709A-4380-B71C-DDB14BA98CA4

Q37114828-6634387C-AF17-49A6-83D0-FD4EED5D96AE

Q37114828-6CAC582E-DEC2-4D2D-A670-9C4C71F5C9D2

P304

Q37114828-0D7656C3-D2BA-4165-A19F-8D26AEDADEAF

P31

Q37114828-0611F23B-6C9B-4C45-8B13-BD2783C30A5F

P356

Q37114828-7979C425-6333-429E-8179-F7ACFEB0EE36

P407

Q37114828-1CAD9A7A-65BF-4E5F-BB6E-6DB662772F69

P433

Q37114828-632AE1B2-3ACC-43EA-B797-2E02595B6D18

P478

Q37114828-0289AB3B-928B-49B2-AB00-9A9D513E93F5

P50

Q37114828-6284CC31-F38B-4BD0-8B0F-12BD937540A6

Q37114828-7EDDC65E-8F4D-4C3E-A617-1FAE5A51321F

P577

Q37114828-AB020DBE-25A3-417C-9546-7CCA4297C56F

P5875

Q37114828-AE062FB2-B348-432D-A5B4-0A5501C320D2

P698

Q37114828-F3552D1D-BB27-4B3A-AE47-E2F34C012B12

P921

Q37114828-57CE255F-6E09-4401-BFCA-AF92CF7C1425

P932

Q37114828-8F7F4424-E5FF-42BF-B594-5F5D61D6B945

P356

PNAS.0712077106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

@en

P2093

Eduardo C DeLa Cruz

http://www.w3.org/2001/XMLSchema#string

Esterlina V Tan

http://www.w3.org/2001/XMLSchema#string

Ian M Orme

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Prieels

http://www.w3.org/2001/XMLSchema#string

Joe Cohen

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Dubois

http://www.w3.org/2001/XMLSchema#string

Mark R Alderson

http://www.w3.org/2001/XMLSchema#string

Pascal Mettens

http://www.w3.org/2001/XMLSchema#string

Randall J Basaraba

http://www.w3.org/2001/XMLSchema#string

Rhea N Coler

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis

Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells

Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG

T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection.

Prospects for a better vaccine against tuberculosis.

The role of programming in memory T-cell development.

Prime-boost immunisation strategies for tuberculosis.

Tuberculosis vaccine development; from mouse to man.

Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection.

P304

2301-2306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0712077106

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Karen D Cowgill

P577

2009-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23972686

http://www.w3.org/2001/XMLSchema#string

P698

19188599

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2650151

http://www.w3.org/2001/XMLSchema#string